Advertisement

Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy

  • Barbara Alicja Jereczek-Fossa
  • Barbara Bortolato
  • Marianna Alessandra GerardiEmail author
  • Samantha Dicuonzo
  • Virginia Maria Arienti
  • Stefania Berlinghieri
  • Stefano Bracelli
  • Michela Buglione
  • Mariangela Caputo
  • Gianpiero Catalano
  • Luigi Franco Cazzaniga
  • Luigi De Cicco
  • Nadia Di Muzio
  • Francesco Romeo Filippone
  • Andrei Fodor
  • Davide Franceschini
  • Paolo Frata
  • Stefania Gottardo
  • Giovanni Battista Ivaldi
  • Antonio Laudati
  • Stefano Maria Magrini
  • Elisa Mantero
  • Ilaria Meaglia
  • Sara Morlino
  • Mauro Palazzi
  • Fabio Piccoli
  • Paola Romanelli
  • Marta Scorsetti
  • Flavia Serafini
  • Luciano Scandolaro
  • Riccardo Valdagni
  • Roberto Orecchia
  • Paolo Antognoni
  • the Lombardy Section of the Italian Society of Oncological Radiotherapy (Associazione Italiana di Radioterapia Oncologica-Lombardia, AIRO-L)
RADIOTHERAPY

Abstract

Aims

To evaluate the use of radiotherapy (RT) for oligometastatic cancer (OMC) among radiation oncologists in Lombardy, Italy.

Methods and study design

A survey with 12 items regarding data of 2016 was sent to all 34 Lombardy RT centers. The survey included six general items and six specific items regarding patient/disease/treatment characteristics.

Results

Thirteen centers answered the survey (38%). All centers responded to general items and 12 centers submitted patient/disease/treatment data. General items The majority of centers (8/13) consider OMC if metastases number is less than 5. The most commonly prescribed dose/fraction is 5–10 Gy (8/13) using schedules of 3–5 fractions (11/13). Patient data items A total of 15.681 patients were treated in 2016 with external beam RT in 12 responding centers, and 1.087 patients were treated for OMC (7%). Primary tumor included lung, prostate, breast, colorectal and other malignancies in 33%, 21%, 12%, 9% and 25% of all OMC patients, respectively. Brain, lymph node, lung, bone, liver and others were the most common treated sites (24%, 24%, 22%, 17%, 8% and 5%, respectively). One and more than one metastasis were treated in 75 and 25% of patients, respectively. The vast majority of patients (95%) were treated with image-guided intensity-modulated RT or stereotactic RT.

Conclusions

Seven percent of all RT patients in Lombardy are treated for OMC. Extreme hypofractionation and high-precision RT are commonly employed. The initiative of multicenter and multidisciplinary collaboration has been undertaken in order to prepare the platform for prospective and/or observational studies in OMC.

Keywords

Oligometastatic cancer Lombardy Radiotherapy Survey Stereotactic body radiotherapy 

Notes

Acknowledgements

We thank the AIRO-Lombardia, for the excellent coordination of the activities through the Lombardy centers, and Fondazione IEO-CCM.

Compliance with ethical standards

Conflict of interest

The authors have no disclosure of potential conflicts of interest.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This is a survey among radiation oncologists. No formal consent is required for this kind of studies.

References

  1. 1.
    Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10CrossRefGoogle Scholar
  2. 2.
    Franklin JM, Sharma RA, Harris AL, Gleeson FV (2016) Imaging oligometastatic cancer before local treatment. Lancet Oncol. 17(9):e406–e414CrossRefGoogle Scholar
  3. 3.
    De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C et al (2017) Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int.  https://doi.org/10.1111/bju.13938 CrossRefPubMedGoogle Scholar
  4. 4.
    Zhao Y, Li J, Li C, Fan J, Liu L (2017) Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: a systematic review and meta-analysis. Int J Surg 41:70–77CrossRefGoogle Scholar
  5. 5.
    Tonyali S, Yazici S (2016) Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies? Int Urol Nephrol 48(5):671–680CrossRefGoogle Scholar
  6. 6.
    Moorcraft SY, Ladas G, Bowcock A, Chau I (2016) Management of resectable colorectal lung metastases. Clin Exp Metastasis 33(3):285–296CrossRefGoogle Scholar
  7. 7.
    Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852–863CrossRefGoogle Scholar
  8. 8.
    Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM (2017) Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer 15(4):e623–e632CrossRefGoogle Scholar
  9. 9.
    Jereczek-Fossa BA, Ronchi S, Orecchia R (2015) Is stereotactic body radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective? Rep Pract Oncol Radiother 20(6):472–483CrossRefGoogle Scholar
  10. 10.
    Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel K et al (2017) Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer 17:361CrossRefGoogle Scholar
  11. 11.
    Berkovic P, De Meerleer G, Delrue L et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 11:27–32CrossRefGoogle Scholar
  12. 12.
    Yeung R, Hamm J, Liu M, Schellenberg D (2017) Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases. Radiat Oncol 12:105CrossRefGoogle Scholar
  13. 13.
    Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A et al (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 116(12):1520–1525CrossRefGoogle Scholar
  14. 14.
    Redmond KJ, Lo SS, Dagan R, Poon I, Foote MC, Erler D et al (2017) A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. Future Oncol. 13(12):1081–1089CrossRefGoogle Scholar
  15. 15.
    Ricardi U, Badellino S, Filippi AR (2016) Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. J Radiat Res 8. pii: rrw006Google Scholar
  16. 16.
    Orecchia R, Surgo A, Muto M, Ferrari A, Piperno G, Gerardi MA et al (2016) VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions. Ecancermedicalscience 29(10):677Google Scholar
  17. 17.
    Scorsetti M, Franceschini D, De Rose F, Comito T, Franzese C, Masci G et al (2017) The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Rep Pract Oncol Radiother 22(2):163–169CrossRefGoogle Scholar
  18. 18.
    Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F et al (2017) Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol 35(1):45–49CrossRefGoogle Scholar
  19. 19.
    Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF (2017) Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up. Clin Colorectal Cancer 16(1):58–64CrossRefGoogle Scholar
  20. 20.
    Jereczek-Fossa BA, Piperno G, Ronchi S, Catalano G, Fodor C, Cambria R (2014) Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol 37(3):227–233CrossRefGoogle Scholar
  21. 21.
    Palazzi M et al (2017) Equipment, staffing and provision of Radiotherapy in Lombardy, Italy: results of three sequential “snapshot” surveys performed between 2012 and 2016. Tumori, AIRO, Thousand OaksGoogle Scholar
  22. 22.
    www.progettorol.it. Accessed 30 June 2017
  23. 23.
    Jereczek-Fossa BA, Colombo R, Magnani T, Fodor C, Gerardi MA, Antognoni P et al (2015) Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy. Tumori 101(2):174–178CrossRefGoogle Scholar
  24. 24.
    Reyes DK, Pienta KJ (2015) The biology and treatment of oligometastatic cancer. Oncotarget 6(11):8491–8524CrossRefGoogle Scholar
  25. 25.
    Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R et al (2017) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73:178–211CrossRefGoogle Scholar
  26. 26.
    Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS et al (2016) Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol 121(1):98–102CrossRefGoogle Scholar
  27. 27.
    Cho JH, Kim S, Namgung M, Choi YS, Kim HK, Zo JI, Shim YM, Kim J (2015) The prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer. World J Surg Oncol. 25(13):222CrossRefGoogle Scholar
  28. 28.
    Pougnet I, Jaegle E, Garcia R, Tessier F, Faivre JC, Louvel G et al (2017) Spinal stereotactic body radiotherapy: French assessment in 2016. Cancer Radiother 21(4):276–285CrossRefGoogle Scholar
  29. 29.
    Kougioumtzopoulou A, Zygogianni A, Liakouli Z, Kypraiou E, Kouloulias V (2017) The role of radiotherapy in bone metastases: A critical review of current literature. Eur J Cancer Care (Engl).  https://doi.org/10.1111/ecc.12724 CrossRefGoogle Scholar
  30. 30.
    Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C et al (2009) Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol 93:14–17CrossRefGoogle Scholar
  31. 31.
    Kroeze SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A et al (2017) Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 53:25–37CrossRefGoogle Scholar
  32. 32.
    Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 37(8):5047–5101CrossRefGoogle Scholar
  33. 33.
    Flickinger JC, Niranjan A (2013) Stereotactic radiosurgery and radiotherapy. In: Halperin EC, Wazer DE, Perez CA, Brady LW (eds) Perez and Brady’s principles and practice of radiation oncology. Lippincott Williams and Wilkins, Philadelphia, pp 351–361Google Scholar
  34. 34.
    Brown JM, Carlson DJ, Brenner DJ (2014) The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 88:254–262CrossRefGoogle Scholar
  35. 35.
    Espenel S, Vallard A, Rancoule C, Garcia MA, Guy JB, Chargari C et al (2017) Melanoma: last call for radiotherapy. Crit Rev Oncol Hematol 110:13–19CrossRefGoogle Scholar
  36. 36.
    Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES et al (2017) A phase II randomized trial of observation versus stereotactic ablative RadiatIon for zLigometastatic prostate CancEr (ORIOLE). BMC Cancer 17:453CrossRefGoogle Scholar
  37. 37.
    Alongi F, Arcangeli S, Triggiani L, Mazzola R, Buglione di Monale E, Bastia M, Fersino S et al (2017) On the behalf of Italian Association of Radiation Oncology [AIRO]. Stereotactic ablative radiation therapy in renal cell carcinoma: from oligometastatic to localized disease. Crit Rev Oncol Hematol 117:48–56CrossRefGoogle Scholar
  38. 38.
    Kwint M, Walraven I, Burgers S, Hartemink K, Klomp H, Knegjens J et al (2017) Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. Lung Cancer 112:134–139CrossRefGoogle Scholar
  39. 39.
    Franzese C, Fogliata A, Comito T, Tozzi A, Iftode C, Clerici E et al (2017) Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. Br J Radiol 90(1079):20170422CrossRefGoogle Scholar
  40. 40.
    Alongi F, Fogliata A, Clerici E et al (2012) Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol 5(7):204CrossRefGoogle Scholar
  41. 41.
    Wild AT, Yamada Y (2017) Treatment options in oligometastatic disease: stereotactic body radiation therapy—focus on colorectal Cancer. Visc Med. 33(1):54–61CrossRefGoogle Scholar
  42. 42.
    AJCC–American Joint Committee on Cancer. https://cancerstaging.org/Pages/default.aspx. Accessed 12 Jan 2018
  43. 43.
    Weichselbaum RR, Liang H, Deng L, Fu YX (2017) Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14(6):365–379CrossRefGoogle Scholar
  44. 44.
    Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672–1682CrossRefGoogle Scholar
  45. 45.
    Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS et al (2017) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 24:e173501Google Scholar
  46. 46.
    De Bleser E, Tran PT, Ost P (2017) Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr Opin Urol.  https://doi.org/10.1097/mou.0000000000000441 CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Medical Radiology 2018

Authors and Affiliations

  • Barbara Alicja Jereczek-Fossa
    • 1
    • 2
  • Barbara Bortolato
    • 3
  • Marianna Alessandra Gerardi
    • 1
    Email author
  • Samantha Dicuonzo
    • 1
  • Virginia Maria Arienti
    • 3
  • Stefania Berlinghieri
    • 4
  • Stefano Bracelli
    • 5
  • Michela Buglione
    • 6
  • Mariangela Caputo
    • 7
  • Gianpiero Catalano
    • 8
  • Luigi Franco Cazzaniga
    • 9
  • Luigi De Cicco
    • 5
  • Nadia Di Muzio
    • 10
  • Francesco Romeo Filippone
    • 9
  • Andrei Fodor
    • 10
  • Davide Franceschini
    • 11
  • Paolo Frata
    • 4
  • Stefania Gottardo
    • 2
    • 15
  • Giovanni Battista Ivaldi
    • 12
  • Antonio Laudati
    • 13
  • Stefano Maria Magrini
    • 6
  • Elisa Mantero
    • 7
  • Ilaria Meaglia
    • 12
  • Sara Morlino
    • 7
  • Mauro Palazzi
    • 3
  • Fabio Piccoli
    • 9
  • Paola Romanelli
    • 1
  • Marta Scorsetti
    • 11
    • 14
  • Flavia Serafini
    • 13
  • Luciano Scandolaro
    • 13
  • Riccardo Valdagni
    • 2
    • 7
    • 16
  • Roberto Orecchia
    • 2
    • 17
  • Paolo Antognoni
    • 15
  • the Lombardy Section of the Italian Society of Oncological Radiotherapy (Associazione Italiana di Radioterapia Oncologica-Lombardia, AIRO-L)
  1. 1.Department of Radiation OncologyEuropean Institute of Oncology IRCCSMilanItaly
  2. 2.Department of Oncology and Hemato-oncologyUniversity of MilanMilanItaly
  3. 3.SC RadioterapiaASST Ospedale NiguardaMilanItaly
  4. 4.Servizio di Radioterapia Ospedale di EsineASST di ValcamonicaEsineItaly
  5. 5.Division of Radiation OncologyASST of Olona ValleyBusto ArsizioItaly
  6. 6.Radioterapia OncologicaUniversità e Spedali CiviliBresciaItaly
  7. 7.Radiation Oncology Unit, Department of Diagnostic Imaging and RadiotherapyFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  8. 8.S.C. RadioterapiaIRCCS MultiMedicaSesto San GiovanniItaly
  9. 9.U.O.C. RadioterapiaASST Papa Giovanni XXIIIBergamoItaly
  10. 10.Department of RadiotherapySan Raffaele Scientific InstituteMilanItaly
  11. 11.Radiotherapy and Radiosurgery DepartmentHumanitas Research Hospital and Cancer CenterRozzano, MilanItaly
  12. 12.Istituti Clinici Scientifici Maugeri PaviaPaviaItaly
  13. 13.UOC di Radioterapia Oncologica, ASST LarianaOspedale S. AnnaComoItaly
  14. 14.Department of Biomedical SciencesHumanitas UniversityRozzano, MilanItaly
  15. 15.S. C. RadioterapiaASST dei Sette Laghi-Ospedale di Circolo e Fondazione MacchiVareseItaly
  16. 16.Prostate Cancer ProgramFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  17. 17.Scientific DirectorateEuropean Institute of OncologyMilanItaly

Personalised recommendations